Article
Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
Scandinavian journal of gastroenterology - 1 Jan 2009
Zheng Song, Pan Yue-Long, Tao De-You, Wang Jiao-Li, Huang Ke-Er
Abstract excerpt
C-kit gene gain of function mutations are important in the pathogenesis of gastrointestinal stromal tumors (GISTs). Imatinib is a selective tyrosine kinase inhibitor of KIT and achieves a partial response or stable disease in most patients with metastatic GIST, but there is increasing evidence of acquired resistance. We report a case of GIST with acquired resistance to imatinib during therapy and secondary c-kit...
Topics
Join the communities discussing this publication.